CN Mobile Logo

Search form


Contemporary Management of Prostate Cancer With Lethal Potential

Contemporary Management of Prostate Cancer With Lethal Potential

In this issue of ONCOLOGY, Davis et al provide a succinct overview of the contemporary management of high-risk prostate cancer patients.[ 1] As the authors point out, the introduction and widespread implementation of prostate-specific antigen (PSA) as a tumor marker has driven a remarkable stage migration in how patients present with prostate cancer, yet a significant number of men continue to present with features placing them at high risk for local treatment failure, development of prostate cancer metastases, and ultimately, death. The authors summarize the significant strides that have been made in identifying the clinical and pathologic prognostic features that distinguish these high-risk men and that have led to the creation of sophisticated statistical modeling techniques such as nomograms to predict PSA recurrence following various local therapies. For example, D'Amico et al developed a system that predicts cancer control in patients treated with radical retropubic prostatectomy, external-beam radiation therapy, or transperineal interstitial permanent brachytherapy, placing them in risk groups based on clinical stage, biopsy Gleason score, and pretreatment PSA level.[2] Nomograms use algorithms that simultaneously integrate multiple variables to calculate the predicted probability that a patient will achieve a particular clinical end point. Nomograms such as those developed by Kattan et al[3] at the Memorial Sloan- Kettering Cancer Center are based on Cox proportional hazards regression analysis. They are widely available and can be downloaded from the Internet (http://www.mskcc.org/mskcc/ html/10115.cfm). Treating the High-Risk Patient
With these tools, clinicians are better able to predict patient outcome, improve patient counseling, and help patients make better treatment decisions.[ 4] By identifying patients at high risk for progression, one would hope that these predictions will assist the clinician in deciding whether to implement adjuvant therapy. But this premise is based on the presumption that an effective adjuvant therapy exists. Despite the advances in our ability to identify, counsel, and prognosticate, what is most striking about the material covered in this review is the utter lack of effective treatment options available for these patients. Contemporary treatment options for clinically localized prostate cancer include radical retropubic prostatectomy[ 5] and radiotherapy given by either external beam[6] or transperineal interstitial permanent implant,[ 7] or a combination of both. It is somewhat distressing, therefore, that it is these identical treatment modalities that are available for highrisk patients, albeit with the use of dose escalation or adjuvant hormonal deprivation therapy-a noncurative treatment modality in use for over 50 years. This situation is rapidly changing with the development of new technologies that enable researchers to gain insights into the biology of prostate cancer and metastasis. Men die not from localized prostate cancer, but from the development of androgenindependent, metastatic prostate cancer. Metastasis is a multistep process in which a cancer cell escapes from the primary tumor, enters either the lymphatic or hematogenous circulation, takes up residence in a distant tissue or organ, develops a new blood supply, and activates other mechanisms that permit it to survive in a foreign environment. Because many steps are involved, it may be possible to block the metastatic process at one or more of these steps. Hormone-Refractory Prostate Cancer
Progression to hormone-refractory prostate cancer remains a major obstacle to effective control of metastatic disease. The treatment of choice for palliation of patients with advanced prostate cancer is withdrawal of androgen by continuous androgen blockade. However, androgen ablation fails to eliminate the entire malignant cell population. Androgen-independent variants acquire alternative growth mechanisms that allow survival of prostate cancer cells and proliferation during androgen deprivation therapy. Understanding the molecular mechanisms and alternative growth pathways induced by androgen deprivation will be crucial before a more rational strategy for the management of prostate cancer can be developed and androgen- independent cell growth can be prevented. Data suggest that the molecular mechanisms underlying the progression of disease during hormonal therapy involve numerous adaptive mechanisms including cell growth, apoptosis, and the development of alternative, non-androgen-based growth-signaling pathways, and that androgen-independent propagation of prostate cancer cells arises as a consequence of the development or upregulation of these alternative autocrine/ paracrine growth signal transduction pathways. It has been demonstrated that a number of growth factors[8] are capable of directly activating the androgen receptor in the absence of the androgen ligand, bypassing normal activation of the hormone-signaling pathway. These changes in the pattern of expression of growth factors and their ligands as prostate cancer progresses from localized androgen deprivation to metastatic androgen- independent disease suggest that inhibition of these autocrine growth factors may be important in the treatment of hormone-refractory prostate cancer. Targeted Therapies
New technologies are promising a new era of "targeted therapies" for targeted patient populations. With tools such as gene expression profiling and proteomics that can identify what is different in the cancer cell and identify aberrantly expressed genes and proteins being expressed in an individual patient's tumor, the possibility of choosing the best targets for therapy and the best patients to receive a targeted therapy is increasingly becoming a reality. This new paradigm is best exemplified by new pharmaceutical agents such as trastuzumab (Herceptin),[9] a monoclonal antibody targeted against HER2/neu that works only in the 30% of patients whose breast tumors are HER2/neu-positive, and imatinib mesylate (Gleevec), a tyrosine-kinase inhibitor that blocks the function of the Bcr-Abl protein, an abnormal fusion protein expressed by the Philadelphia chromosome that contributes to the rapid reproduction of white blood cells in patients with chronic myelogenous leukemia.[10] These new agents are used in an attempt to disrupt pathways unique to cancer cells, while theoretically leaving normal cancer cells alone and avoiding the toxic side effects commonly associated with chemotherapy and radiation. Clinical trials of targeted therapies in men with high-risk prostate cancer are under way. One such study involves oral CCI-779 in newly diagnosed prostate cancer patients undergoing radical prostatectomy who are at high risk for disease relapse (http://www.clinicaltrials.gov/ct/ show/NCT00071968?order=47). CCI-779 inhibits translation of several key proteins that regulate the G1 phase of the cell cycle by binding to the intracellular cytoplasmic protein FKBP-12.[11] The complex of CCI-779 and FKBP-12 blocks the activity of a kinase-the mammalian target of rapamycin (mTOR)-and subsequently inhibits key signaling pathways, including those regulated by p70S kinase and 4E-BP1, thereby blocking the G1 phase of the cell cycle.[ 12] This pathway is downstream from the tumor-suppressor gene PTEN, and mutations of PTEN have been implicated in several cancers, including prostate cancer.[13] Preliminary in vitro studies in a number of tumor types, including prostate cancer, have demonstrated a correlation between PTEN loss and sensitivity to growth inhibition by CCI-779.[14] This study is designed to evaluate the effect of CCI-779 in men with PTENnormal vs PTEN-mutated prostate cancer tumors. Conclusions
Davis et al aptly summarize the contemporary management of highrisk prostate cancer patients, focusing on currently available standards of care. Yet wider surgical margins, escalation of radiotherapy dose, and use of adjuvant hormonal deprivation therapy can only be expected to incrementally improve the outcome in high-risk prostate cancer patients. The management of these patients remains an extraordinary clinical challenge, but advances in technology and an increased understanding of tumor biology have opened the door to a new paradigm for their treatment.


The authors have no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.


1. Davis JW, Shaves ME, Schellhammer PF: The high-risk patient: Contemporary management of prostate cancer with lethal potential. Oncology 18:811-820, 2004.
2. D’Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998.
3. Kattan MW, Wheeler TM, Scardino PT: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17:1499-1507, 1999.
4. Ross PL, Scardino PT, Kattan MW: A catalog of prostate cancer nomograms. J Urol 165:1562-1568, 2001.
5. Catalona WJ, Smith DS: Five-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 152:1837-1842, 1994.
6. Hanks GE, Lee WR, Schultheiss TE: Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol 154:456-459, 1995.
7. Ragde H, Blasko JC, Grimm PD, et al: Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 80:442- 453, 1997.
8. Mizokami A, Saiga H, Matsui T, et al: Regulation of androgen receptor by androgen and epidermal growth factor in a human prostatic cancer cell line, LNCaP. Endocrinol Jpn 39:235-243, 1992.
9. Umemura S, Sakamoto G, Sasano H, et al: Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (Pathological Committee for optimal use of trastuzumab). Breast Cancer 8:316-320, 2001.
10. Shah NP, Sawyers CL: Mechanisms of resistance to STI571 in Philadelphia chromosome- associated leukemias. Oncogene 22:7389-7395, 2003.
11. Peralba JM, DeGraffenried L, Friedrichs W, et al: Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9:2887-2892, 2003.
12. Dudkin L, Dilling MB, Cheshire PJ, et al: Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 7:1758- 1764, 2001.
13. Whang YE, Wu X, Suzuki H, et al: Inactivation of the tumor suppressor PTEN/ MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A 95:5246-5250, 1998.
14. Neshat MS, Mellinghoff IK, Tran C, et al: Enhanced sensitivity of PTENdeficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 98:10314-10319, 2001.
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.